Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 5/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.39 |
| ▸ | FSHR | P23945 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797654 | 0.84 | LPAR1 (0.43) | MLNRLPAR1HDAC1HDAC6HDAC3 | |
| SCHEMBL1801655 | 0.82 | HDAC1 (0.38) | NR1H2HDAC1HDAC6CYP4F2CYP4A11 | |
| SCHEMBL1799338 | 0.78 | RAF1 (0.42) | KDM4E | |
| SCHEMBL1799805 | 0.76 | HDAC1 (0.51) | LPAR1HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL1797650 | 0.76 | PTGER1 (0.38) | MLNRLPAR1LTB4R2 | |
| SCHEMBL1797652 | 0.76 | PTGER1 (0.38) | MLNRLPAR1LTB4R2 | |
| SCHEMBL1798901 | 0.73 | HDAC1 (0.52) | LPAR1HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL8697074 | 0.71 | NR1H2 (0.42) | MLNRFSHRNR1H2HDAC1HDAC3 | |
| SCHEMBL1802397 | 0.71 | HDAC1 (0.43) | LPAR1NR1H2HDAC1CYP4F2CYP4A11 | |
| SCHEMBL1802560 | 0.70 | SSTR4 (0.43) | LPAR1HDAC1HDAC6KDM4EHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | MLNR 355/4885LPAR1 845/4885FSHR 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.